theliatinib

Theliatinib, a potent and highly selective EGFR inhibitor, with anti-tumor activity. Ki of 0.05 nM for wild type EGFR, and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant, respectively.

Theliatinib (Xiliertinib) tartrate is a potent and highly selective EGFR inhibitor with ATP-competitive and orally active properties, showing a K_i of 0.05 nM and an IC_50 of 3 nM for EGFR, and an IC_50 of 22 nM for the EGFR T790M/L858R mutant, with over 50-fold selectivity for EGFR compared to other kinases.